NCT04738695View on ClinicalTrials.gov

SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)

CompletedOBSERVATIONAL
Enrollment

3,008

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Covid19SARS-CoV-2 Infection
Interventions
DIAGNOSTIC_TEST

Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)

Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers

Trial Locations (1)

9000

Ghent University, Ghent

All Listed Sponsors
collaborator

KU Leuven

OTHER

collaborator

University of Liege

OTHER

collaborator

Universiteit Antwerpen

OTHER

lead

Sciensano

OTHER_GOV

NCT04738695 - SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19) | Biotech Hunter | Biotech Hunter